AAN

In the MOTION and SETTLE studies, safinamide was shown to be effective in the treatment of patients with Parkinson's disease as add-on therapy to a stable dose of a single dopamine agonist and as add-on therapy for patients taking levodopa.

Switching from oral administration of the non-ergoline dopamine agonist, rotigotine, to a transdermal delivery system may improve gastrointestinal symptoms for patients with Parkinson's disease.

Fernando Figueira, MD, and his associates from the Hospital São Francisco, in Rio De Janeiro, Brazil, called for expanded requirements for "disease-free" designation in multiple sclerosis (MS) patients in a Multiple Sclerosis Treatment poster session at the American Academy of Neurology (AAN) 2013 Annual Meeting.

In the Multiple Sclerosis Treatment Safety poster session at the American Academy of Neurology (AAN) 2013 Annual Meeting, Barry Singer, a neurologist at the Missouri Baptist Medical Center, in St. Louis, and founder and director of the MS Center for Innovations in Care, and his co-authors presented an analysis of infection rates in three placebo-controlled teriflunomide studies.

In the Multiple Sclerosis Treatment Safety poster session at the American Academy of Neurology (AAN) 2013 Annual Meeting, Paul O'Connor, of St. Michael's Hospital, in Toronto, and his colleagues presented a study designed to determine whether immune responses to seasonal influenza vaccination are preserved in teriflunomide-treated patients with relapsing forms of multiple sclerosis (RMS).

Seminar at the American Academy of Neurology annual meeting discusses the systematic approach to diagnosing patients with MS, initial medication selection, and changing treatments.

Disease activity, patient preference, and other factors should be considered when selecting DMT for the treatment of multiple sclerosis.

Study results suggest that age and timing of treatment initiation with interferon beta therapy may play a larger role than relapse in long-term disability in patients with multiple sclerosis.

News and updates about AAN 2013, the 65th Annual Meeting of the American Academy of Neurology.

In the first long-term active-comparator trial of efficacy and augmentation in restless leg syndrome (RLS), outcomes with pregabalin were better than those observed with pramipexole.

Although the intra-cerebral hemorrhage (ICH) score at hospital admission is typically used to estimate the potential prognosis in stroke patients, a new study suggests that the 24-hour ICH score is a more accurate assessment.

According to a randomized, controlled clinical trial reported at the Emerging Science session, pregabalin was found effective in relieving chronic neuropathic pain and pain-related sleep disturbances associated with spinal cord injury.

Results from the FREEDOMS II trial found oral fingolimod administered at a daily dose of 0.5 mg to reduce relapse rates by almost 50% in patients with relapsing-remitting multiple sclerosis (RRMS).

Mark F. Mehler, MD, discussed how brain and behavior are becoming better understood through the emerging discipline of epigenetics.

The 2012 Annual Meeting of the American Academy of Neurology presented a phase 3 randomized, double-blind clinical trial which found that levodopa-carbidopa intestinal gel was more effective than standard oral levodopa-carbidopa.

An investigational oral drug for multiple sclerosis (MS), called ONO-4641, reduced the number of lesions detected on magnetic resonance imaging (MRI) scans

Updated guidelines for prevention of chronic migraine headache were unveiled during the 2012 Annual Meeting of the American Academy of Neurology.

A new study presented at the 2012 Annual Meeting of the American Academy of Neurology suggests that the drug florbetaben can be used as a biomarker with positron emission tomography (PET) imaging to diagnose AD by detecting amyloid plaques in the brains of living people suspected of having AD.

Dr. Sacco highlights some of the key takeaway points that he will speaking about during the Robert Wartenberg Lecture at this year's AAN Annual Meeting. He also discusses his involvement in the Northern Manhattan Study, which evaluates stroke in African and Hispanic Americans.

In this interview, Michael Zigmond, PhD, previews his lecture to be given at this year's AAN Annual Meeting. Zigmond explains how he became involved with studying Parkinson's disease (PD), research with exercise and PD, and what his intentions are with helping to fight this disease.

At this year's AAN Annual Meeting, attendees will find exciting ways to explore New Orleans and can take advantage of the various downtime activities hosted by the AAN such as morning yoga or tennis.

This year's American Academy of Neurology Annual Meeting is being hosted in New Orleans, LA from April 21-27, which is known for its ecletic cuisine. Here are some ideas of restaurants to check out.

At this year's meeting, the AAN will be hosting various scientific and plenary session focusing on the hot topics in neurology.

Study finds no improvement in cognitive impairment among patients with multiple sclerosis treated with ginkgo biloba extract.

Slow-release formulation of zinc is safe for Alzheimer's disease patients, and effectively raises serum zinc levels, but does not benefit cognition.

Safinamide improves "on time" and other symptoms and reduces dyskinesias in patients with Parkinson's disease.

Study results show that oral laquinimod reduces the annual relapse rate in patients with relapsing-remitting multiple sclerosis.

Patients treated with Qutenza reported significant relief from pain associated with PHN, regardless of gender, age, PHN duration, or baseline pain score.

Selegiline inhibits MAO-A in the brain of patients with Parkinson's Disease without elevating the risk of hypertensive crisis from dietary tyramine.

Results from the CLARITY study show cladribine reduces the relapse rate in multiple sclerosis patients who have failed other disease-modifying therapies.